Opinion | April 17, 2025
Injection filter needle market to reach $1.73 billion in 2025
Rising demands and advancements in eye care drive growth
Rising demands and advancements in eye care drive growth
Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME)
Demonstrates vision gains with extended treatment intervals in retinal vein occlusion
Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept
Susvimo is a unique therapeutic approach that provides continuous delivery of medicine to the eye through a refillable implant
Acquisition strengthens and diversifies Merck’s pipeline with the addition of Restoret
Vabysmo PFS is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that can cause blindness
Acquisition includes Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration
Subscribe To Our Newsletter & Stay Updated
